Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

1. Restoring oscillatory dynamics in Alzheimer's disease: A laminar whole-brain model of serotonergic psychedelic effects.Network neuroscience (Cambridge, Mass.) · 2026
   Article
2. Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Dialogues in clinical neuroscience · 2025
   Review
3. Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.Cells · 2025
   Article
4. Exploring the impact of the liver-intestine-brain axis on brain function in non-alcoholic fatty liver disease.Journal of pharmaceutical analysis · 2025
   Article
5. Psychedelics and schizophrenia: a double-edged sword.Molecular psychiatry · 2025
   Review
6. Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms.GeroScience · 2025
   Review
7. Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.Frontiers in systems neuroscience · 2025
   Review
8. Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.Frontiers in dementia · 2025
   Review
9. Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2024
   Review
10. Alterations in Neuronal Nicotinic Acetylcholine Receptors in the Pathogenesis of Various Cognitive Impairments.CNS neuroscience & therapeutics · 2024
    Review
11. Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
12. Psilocybin for the treatment of Alzheimer's disease.Frontiers in neuroscience · 2024
    Review
13. Deep CANALs: a deep learning approach to refining the canalization theory of psychopathology.Neuroscience of consciousness · 2024
    Article
14. Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.Psychedelic medicine (New Rochelle, N.Y.) · 2023
    Review
15. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023
    Review
16. Psychedelics and fNIRS neuroimaging: exploring new opportunities.Neurophotonics · 2023
    Article
17. Azepine-Indole Alkaloids FromFrontiers in neuroscience · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as